Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee...

Advanced Cell Technology's Executive Invited to Present Today to FDA Advisory Committee on Cellular Tissue Therapies

ALAMEDA, Calif.--(Business Wire)--
Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that
Jonathan H. Dinsmore Ph.D., Senior Vice President - Regulatory and
Clinical, has been invited to present to the U.S. Food and Drug
Administration's Center for Biologics Evaluation and Research Advisory
Committee on Cellular, Tissue and Gene Therapies. Dr. Dinsmore will
deliver a presentation today titled, "Safety Considerations for the
Clinical Application of Human Embryonic Stem Cells" to the FDA panel,
which will convene at the Hilton Hotel in Gaithersburg, Maryland. The
presentation is scheduled for 10 a.m. eastern time. The panel is
expected to conduct hearings on Cellular Therapies Derived from Human
Embryonic Stem Cells Scientific Considerations for Pre-Clinical Safety
Testing. Other companies invited to present include Geron Corporation
(NASDAQ: GERN) and Novocell, Inc.

During Dr. Dinsmore's presentation, he is expected to discuss cell
sourcing, manufacturing and delivery of human embryonic stem cells. He
will also present certain conclusions from pre-clinical activities
surrounding the company's retinal pigmented epithelial (RPE) cell
therapy. Advanced Cell recently completed discussions with the FDA
regarding this program through a type B, pre-Investigational New Drug
(pre-IND) meeting concerning the regulatory pathway and requirements
to file an IND to initiate human clinical trials. The entire
presentation will be available on the company's web site at
http://www.advancedcell.com/conference-presentations after 11 a.m.
eastern time today.

"We are honored that the FDA has invited us to participate in this
panel, which could be influential in shaping the clinical pathway for
the testing of embryonic stem cells," said William M. Caldwell IV,
Chairman and CEO of Advanced Cell Technology, Inc. "As one of the few
stem cell companies that is preparing for later-stage clinical trials,
we are pleased that we will be able to share our views with FDA
executives and other distinguished members of the scientific community
on the safety issues surrounding human embryonic stem cell
development."

Additional details on the FDA meeting may be found at
http://www.fda.gov/ohrms/dockets/ac/cber08.html#CellularTissueGene
Therapies (Due to its length, this URL may need to be copied/pasted
into your Internet browser's address field. Remove the extra space if
one exists).

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying
cellular technology in the emerging field of regenerative medicine.
The company operates facilities in California and Massachusetts.

For more information, visit www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and
operating results, future growth in research and development programs,
potential applications of our technology, opportunities for the
company and any other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not
statements of historical fact (including statements containing the
words "will," "believes," "plans," "anticipates," "expects,"
"estimates," and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, including: limited
operating history, need for future capital, risks inherent in the
development and commercialization of potential products, protection of
our intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the company's periodic reports, including the report on Form
10-QSB for the quarter ended September 30, 2007. Forward-looking
statements are based on the beliefs, opinions, and expectations of the
company's management at the time they are made, and the company does
not assume any obligation to update its forward-looking statements if
those beliefs, opinions, expectations, or other circumstances should
change.

Forward-looking statements are based on the beliefs, opinions, and
expectations of the company's management at the time they are made,
and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations,
or other circumstances should change.

CEOcast, Inc. for Advanced Cell Technology
Daniel Schustack, 212-732-4300

Copyright Business Wire 2008